Denali therapeutics announces new interim data from phase 1/2 study of dnl310 (etv:ids) in mps ii (hunter syndrome) at ssiem 2023

South san francisco, calif., aug. 30, 2023 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new interim data from the ongoing open-label, single-arm phase 1/2 study of dnl310 (etv:ids) in children with mps ii (hunter syndrome). dnl310 is an investigational enzyme replacement therapy designed to cross the bbb and address the behavioral, cognitive, and physical manifestations of mps ii. the interim data from the phase 1/2 study of dnl310 were highlighted in an oral presentation at the society for the study of inborn errors of metabolism (ssiem) annual symposium 2023 in jerusalem, israel. a pdf of the phase 1/2 presentation is available on denali's website on the events page of the investor section.
DNLI Ratings Summary
DNLI Quant Ranking